Incyte Corp Stock Price, News & Analysis

Incyte (NASDAQ: INCY) said it will report third quarter 2025 financial results with a press release on October 28, 2025 at 7:00 a.m. ET and a conference call and webcast on October 28, 2025 at 8:00 a.m. ET. Domestic dial-in is 877-407-3042, international dial-in is 201-389-0864, and the conference ID is 13756261. A replay of the call will be available for 30 days (U.S. replay 877-660-6853; international replay 201-612-7415) and the webcast replay with slides will be available at Investor.Incyte.com for 90 days.

Incyte (Nasdaq:INCY) has granted equity inducement awards to David H. Gardner, the company's new Executive Vice President and Chief Strategy Officer. The compensation package includes:

• 42,899 stock options at $84.73 per share with a ten-year term
• 9,429 restricted stock units (RSUs)
• 23,573 target performance shares tied to TSR performance

The awards, approved under Nasdaq Rule 5635(c)(4), include specific vesting schedules and performance criteria over a three-year period beginning January 1, 2025.

Incyte (Nasdaq:INCY) has appointed Dave Gardner as Executive Vice President and Chief Strategy Officer, effective September 22, 2025. Gardner brings over 20 years of experience in pharmaceutical and biotechnology investing and advising, most recently serving as Partner at Rock Springs Capital Management.

In his new role, Gardner will be responsible for the company's strategy and business development, joining the Executive Leadership Team. He previously held positions at BlackRock as Vice President and Equity Research Analyst. The appointment coincides with the retirement of Vijay Iyengar, M.D., who served nine years as EVP and Head of Global Medical Affairs and Product and Partnership Strategy.

Incyte (NASDAQ:INCY) has received FDA approval for Opzelura® (ruxolitinib) cream 1.5% to treat mild to moderate atopic dermatitis in non-immunocompromised children aged 2-11 years. This marks Opzelura's third FDA approval, making it the first topical JAK inhibitor approved for pediatric atopic dermatitis in the U.S.

The approval is based on the Phase 3 TRuE-AD3 trial, which demonstrated significant efficacy in achieving Investigator's Global Assessment-treatment success and 75% improvement in the Eczema Area and Severity Index. The treatment showed a consistent safety profile with no new concerns identified. This expansion addresses an estimated 2-3 million patients aged 2-11 in the U.S. affected by atopic dermatitis.

Incyte (Nasdaq:INCY) announced promising 24-week interim data from its Phase 3 STOP-HS clinical trials for povorcitinib, an oral JAK1 inhibitor for hidradenitis suppurativa (HS). The trials demonstrated statistically significant improvements in patients with moderate to severe HS.

Key findings include: Nearly 60% of patients achieved HiSCR50 (≥50% reduction in inflammatory lesions) at Week 24. Additional endpoints showed 31.0%-40.3% achieved HiSCR75, 13.8%-27.7% reached HiSCR90, and 9.2%-21.3% attained HiSCR100. Notably, 62%-70% of patients reported mild or no pain by Week 24.

The data will support regulatory submissions in Europe (2025) and the United States (early 2026). The treatment demonstrated a consistent safety profile with previous data, with both 45mg and 75mg doses well-tolerated.

Incyte (NASDAQ:INCY) will present new data from its dermatology portfolio at the EADV 2025 Congress in Paris from September 17-20. The presentations will highlight key findings from multiple clinical trials, including a late-breaking presentation of 24-week data from the Phase 3 STOP-HS trial of povorcitinib for hidradenitis suppurativa.

The company will showcase results across multiple dermatological conditions, featuring data on povorcitinib (an oral JAK1 inhibitor) and ruxolitinib cream (Opzelura®) (a topical JAK1/2 inhibitor). Presentations will cover treatments for conditions including hidradenitis suppurativa, prurigo nodularis, vitiligo, and atopic dermatitis.

Incyte (Nasdaq:INCY) has launched HS TRUTHS, an educational campaign focused on revealing the realities of living with hidradenitis suppurativa (HS), a chronic inflammatory skin condition. The campaign features authentic stories from HS patients highlighting both physical and emotional impacts of the disease.

HS affects approximately 1% of the population and is characterized by painful nodules and abscesses that can cause permanent tissue damage. The condition significantly impacts patients' daily lives, with diagnosis often taking 7-10 years. A recent survey revealed that 75% of patients experience negative emotions during healthcare discussions.

The initiative aims to improve patient-provider communication and increase understanding of HS's comprehensive impact through unfiltered patient testimonials.

Incyte (Nasdaq: INCY) announced equity inducement awards for Soni Basi, the company's new Executive Vice President and Chief Human Resources Officer. The compensation package includes:

- 29,230 stock options at $84.76 per share, vesting over 4 years
- 6,506 restricted stock units (RSUs), vesting 25% annually over 4 years
- 16,265 target performance shares based on 3-year TSR performance, potentially earning 0-200% of target

The awards were granted under Incyte's 2024 Inducement Stock Incentive Plan and approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).

Incyte (Nasdaq:INCY) has appointed Soni Basi as Executive Vice President and Chief Human Resources Officer (CHRO), effective August 25, 2025. As a key member of the Executive Leadership Team, Basi will lead the company's global HR strategy, focusing on talent acquisition, organizational design, and professional development.

Basi brings over 25 years of experience in global HR and business leadership, previously serving as CHRO at Edelman where she managed 200+ HR professionals. Her prior experience includes leadership roles at AIG, Allergan Pharmaceuticals, The Estée Lauder Companies, and Schering-Plough. She succeeds Paula Swain, who has retired from her position as Executive Vice President and Head of Human Resources.